MARKET

QLGN

QLGN

Qualigen Therapeutics Inc
NASDAQ
0.4488
-0.0113
-2.46%
After Hours: 0.4599 +0.0111 +2.47% 19:28 03/01 EST
OPEN
0.4821
PREV CLOSE
0.4601
HIGH
0.4821
LOW
0.4350
VOLUME
78.50K
TURNOVER
0
52 WEEK HIGH
1.380
52 WEEK LOW
0.4350
MARKET CAP
2.33M
P/E (TTM)
-0.1214
1D
5D
1M
3M
1Y
5Y
12 Health Care Stocks Moving In Tuesday's Intraday Session
Janux Therapeutics (NASDAQ:JANX) stock increased by 189.9% to $43.78 during Tuesday's regular session. The company's market cap stands at $2.0 billion. Viking Therapeutic shares moved upwards by 91.96% as the company's Q4 earnings report came out.
Benzinga · 6d ago
Qualigen Therapeutics Secures Investment and Expands Financing Options
TipRanks · 6d ago
Weekly Report: what happened at QLGN last week (0219-0223)?
Weekly Report · 02/26 12:29
Qualigen Therapeutics Inks Exclusive RAS Program Deal
TipRanks · 02/22 21:25
Weekly Report: what happened at QLGN last week (0212-0216)?
Weekly Report · 02/19 12:32
Qualigen Therapeutics New Publication Released In The Nature Scientific Reports Journal Titled "Structure–Activity Relationships For The G-Quadruplex-Targeting Experimental Drug QN-302 And Two Analogues Probed With Comparative Transcriptome Profiling And Molecular Modeling"
Benzinga · 02/12 16:51
Weekly Report: what happened at QLGN last week (0205-0209)?
Weekly Report · 02/12 12:16
Weekly Report: what happened at QLGN last week (0129-0202)?
Weekly Report · 02/05 12:29
More
About QLGN
Qualigen Therapeutics, Inc. is a diversified life sciences company. The Company is focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug designation, while also commercializing diagnostics. Its cancer therapeutics pipeline includes QN-302, RAS and QN-247. QN-302 is a small molecule genomic quadruplex (G4) selective transcription inhibitor with a strong binding affinity to G4s prevalent in cancer cells. RAS is a family of rat sarcoma virus (RAS) oncogene protein-protein interaction inhibitor small molecules for preventing mutated RAS genes’ proteins from binding to their effector proteins; preventing this binding could stop tumor growth, especially in RAS-driven tumors such as pancreatic, colorectal and lung cancers. QN-247 is a deoxyribonucleic acid (DNA) coated gold nanoparticle cancer drug candidate that has the potential to target various types of cancer, including triple negative breast cancer, acute myeloid leukemia (AML) and glioblastoma.

Webull offers Qualigen Therapeutics Inc stock information, including NASDAQ: QLGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, QLGN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading QLGN stock methods without spending real money on the virtual paper trading platform.